Drug intelligence / Profile preview

VT10

Development stage: Unknown
Lead developer: Venthera
Modality: Small Molecules
Administration: Topical

Overview

VT10 is an active drug form that is rapidly metabolized from the prodrug VT30 in the skin. VT30, developed by Venthera, Inc., a BridgeBio company, is a topical treatment intended for cutaneous venous malformations, lymphatic malformations, or mixed venolymphatic malformations associated with PIK3CA or TEK mutations. As the active form, VT10 is expected to achieve target engagement by inhibiting inappropriate PI3K activation and addressing TEK mutations, thereby contributing to the amelioration of the signs and symptoms of these malformations.

Targets

PIK3CA (Phosphoinositide 3-kinase alpha)

Beyond the preview

Go deeper on VT10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VT10.

Explore the full profile